https://idataresearch.com/wp-content/themes/lambda-child-theme/images/footer-logo.png
https://idataresearch.com/wp-content/themes/lambda-child-theme/images/idata-white-logo.png

Immunology

The immunology drugs market size is growing steadily and with biosimilars already beginning to affect the market it will become more active. As the population ages and more people are looking for effective drugs for a host of maladies, the scope of immunology drugs market research is expanding at a significant rate.

Click Here to Learn About Our Global Capabilities in Immunology Drugs Market Research

Markets included within immunology drugs includes: Crohn’s Disease Drug Market, Rheumatoid Arthritis Drug Market, Psoriasis Drug Market, Ulcerative Colitis Drug Market, and the Ankylosing Spondylitis Drug Market. iData Research has done extensive immunology drugs market analysis to give you access to important and accurate market trends. Our reports let you know exactly where you should direct your efforts.

Showing all 2 results

Immunology Drugs Market Overview | Europe | 2018-2024 | MedView

The Europe immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics.

more...

Immunology Drugs Market Overview | United States | 2018-2024 | MedView

The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

more...